Does Christiana Care Health System Cover Vyvanse?

What Christiana Care Health System Actually Is and Does Not Do

Christiana Care Health System (now operating as ChristianaCare) is a large, not-for-profit health system based in Wilmington, Delaware. It runs hospitals, outpatient clinics, a medical group, and a health plan subsidiary called ChristianaCare Health Plans. That distinction matters.

As a hospital system, ChristianaCare prescribes and sometimes dispenses medications inside its facilities, but it does not set commercial formularies for the insurance plans most patients carry. Your drug coverage is controlled by whoever underwrites your health insurance, whether that is a private insurer like Aetna or Highmark, a Delaware Medicaid managed care organization, Medicare Part D plan, or ChristianaCare Health Plans if you are enrolled in one of their employer or ACA marketplace products.

ChristianaCare Health Plans vs. The Hospital System

ChristianaCare Health Plans is a separate subsidiary. It offers employer-sponsored group coverage and individual plans in Delaware and parts of Maryland and Pennsylvania. If your insurance card reads "ChristianaCare Health Plans," your Vyvanse benefit is governed by that plan's drug formulary, not by the hospital's prescribing policies.

If your card reads something else, such as Highmark Delaware, Aetna, or UnitedHealthcare, ChristianaCare's clinical staff can prescribe Vyvanse but have no authority over whether your insurer pays for it.

Why This Distinction Changes Your Next Step

Patients sometimes assume that seeing a ChristianaCare physician guarantees that prescriptions will be covered. The prescribing decision and the payment decision live in two entirely separate systems. A ChristianaCare psychiatrist or primary care physician can and does prescribe Vyvanse when it is clinically appropriate. Whether your insurer will pay for it at the pharmacy counter is a separate question answered by your plan's formulary.

What Is Vyvanse and Why Coverage Is Often Contested

Vyvanse (lisdexamfetamine dimesylate) is a prodrug stimulant converted in the body to d-amphetamine. The FDA approved it in 2007 for ADHD in children ages 6 to 17, later extended to adults, and again in 2015 for moderate-to-severe binge eating disorder (BED) in adults. [1]

Because it is a Schedule II controlled substance and was long a brand-only drug commanding a high list price, insurers developed aggressive management tools around it.

FDA-Approved Indications

• ADHD (attention-deficit/hyperactivity disorder) in patients age 6 and older
• Moderate-to-severe binge eating disorder in adults (the only FDA-approved pharmacotherapy for BED as of this writing)

Clinical data supporting the BED indication come from two key phase 3 trials (SPD489-343 and SPD489-344, combined N>700) in which lisdexamfetamine 50 mg and 70 mg significantly reduced binge-eating days per week versus placebo (P<0.001). [2]

Generic Lisdexamfetamine

The FDA approved generic lisdexamfetamine dimesylate capsules in 2023 after the expiration of Takeda's exclusivity period. Generic availability has been uneven at retail pharmacies, but the entry of generics means many insurers now tier branded Vyvanse as non-preferred or require generic substitution where available. [3]

How Insurance Formularies Work for Stimulant Medications

A formulary is a tiered list of covered drugs. Most commercial plans place stimulants on Tier 2 (preferred brand), Tier 3 (non-preferred brand), or increasingly Tier 1 (generic preferred) now that generic lisdexamfetamine exists. Government programs apply additional scrutiny.

Tier Placement and Cost-Sharing

| Formulary Tier | Typical Patient Cost | Example | |---|---|---| | Tier 1 (generic preferred) | $10, $30 co-pay | Generic lisdexamfetamine | | Tier 2 (preferred brand) | $40, $80 co-pay | Branded Vyvanse on some plans | | Tier 3 (non-preferred brand) | $80, $150+ co-pay | Branded Vyvanse on many plans | | Not covered / excluded | Full list price (~$400/month) | Some restrictive plans |

These figures are representative ranges. Your actual cost-sharing depends on your specific plan document.

Prior Authorization Requirements

Prior authorization (PA) is a process by which your prescriber documents medical necessity before the insurer agrees to pay. For Vyvanse, PA criteria typically require:

1. A confirmed diagnosis of ADHD or BED from a licensed clinician.
2. Documentation of a trial of at least one first-line stimulant (often methylphenidate or mixed amphetamine salts) unless contraindicated.
3. Evidence that the alternative was ineffective, poorly tolerated, or that a clinical reason exists to start directly with lisdexamfetamine (for example, BED, since no other approved stimulant carries that indication).

The American Academy of Child and Adolescent Psychiatry's 2020 Practice Parameter notes that stimulant medications are first-line pharmacotherapy for ADHD and that prior authorization barriers "delay initiation of effective treatment and place administrative burdens on clinicians." [4]

Step Therapy ("Fail First") Policies

Step therapy requires patients to try and fail a less-expensive drug before the insurer approves the originally prescribed agent. Delaware enacted step-therapy reform legislation (Senate Bill 48, signed 2019) requiring insurers to grant exceptions when step therapy is clinically inappropriate, which gives prescribers a formal pathway to bypass the protocol. [5]

Delaware Medicaid and CHIP Coverage of Vyvanse

Delaware's Medicaid program operates through managed care organizations including AmeriHealth Caritas Delaware and Highmark Health Options. Each MCO maintains its own preferred drug list (PDL) that must conform to Delaware's statewide PDL managed by the Division of Medicaid and Medical Assistance (DMMA).

Current Preferred Drug List Status

As of the most recent Delaware DMMA PDL review cycles, generic lisdexamfetamine is designated preferred for ADHD when it is available at the dispensing pharmacy. Branded Vyvanse may require PA and documentation that the generic formulation is unavailable or clinically inappropriate. For the BED indication, coverage may require specialist documentation because BED is still under-recognized in primary care settings.

Patients covered through Delaware Medicaid who receive care at a ChristianaCare facility should verify Vyvanse coverage directly with their MCO's pharmacy help line, as PDL updates occur quarterly.

CHIP (Children's Health Insurance Program)

Delaware's CHIP program (Healthy Children Program) follows the same managed care structure. Children with ADHD diagnosed by a ChristianaCare developmental-behavioral pediatrician or psychiatrist may qualify for Vyvanse under PA, particularly if amphetamine salts caused adverse effects. CHIP enrollees have the same step-therapy exception rights as adult Medicaid enrollees under SB 48.

Medicare Part D and Vyvanse

Medicare Part D plans cover most Schedule II stimulants, including lisdexamfetamine, but the Controlled Substances Act historically complicated reimbursement. The SUPPORT for Patients and Communities Act (2018) amended prescribing rules to allow electronic prescribing of Schedule II drugs, easing the access pathway somewhat. [6]

For adults aged 65 and older being treated for ADHD or BED by a ChristianaCare provider, a Medicare Part D plan sponsor determines formulary status. The Low Income Subsidy (Extra Help program) may reduce or eliminate out-of-pocket costs for eligible beneficiaries. [7]

ChristianaCare Employee Health Plan Coverage

ChristianaCare's own employee health benefits are administered through a third-party administrator and subject to change annually during open enrollment. Employees enrolled in a ChristianaCare-sponsored plan should consult:

• The Summary of Benefits and Coverage (SBC) document provided during enrollment.
• The plan's online formulary lookup tool.
• ChristianaCare's Employee Assistance Program (EAP) or HR benefits line for guidance on mental health medications.

Benefits managers can confirm whether generic lisdexamfetamine is preferred, whether branded Vyvanse is on formulary, and what the PA requirements are for the current plan year.

How to Get Prior Authorization Approved Through a ChristianaCare Prescriber

ChristianaCare's outpatient psychiatry, primary care, and behavioral health teams handle PA requests routinely. The process generally moves faster when the prescriber's office submits clinical documentation proactively rather than waiting for a denial.

Step 1: Confirm the Diagnosis in Writing

A PA request for Vyvanse should include a documented ADHD or BED diagnosis using DSM-5 criteria. For ADHD, rating scales such as the Conners Adult ADHD Rating Scales or the Vanderbilt Assessment Scale (for children) provide objective data that strengthen the submission.

Step 2: Document Step-Therapy History or Exception Criteria

If the patient previously tried methylphenidate (e.g., Concerta, Ritalin) or mixed amphetamine salts (Adderall) and experienced inadequate response or intolerable side effects, include those treatment dates, doses, and outcomes. If the indication is BED, note explicitly that no other FDA-approved pharmacotherapy for BED exists, because this is a strong clinical rationale for bypassing step therapy.

Step 3: Invoke Delaware's Step-Therapy Exception Law if Needed

Delaware's 2019 step-therapy reform (SB 48) requires insurers to grant an exception within 72 hours (or 24 hours for urgent cases) when a prescriber certifies that the required drug would cause adverse effects, is contraindicated, or has already been tried and failed. ChristianaCare's prescribers can submit a written certification to trigger this process. [5]

Step 4: Appeal a Denial

If the PA is denied, patients have a right to an internal appeal under the Affordable Care Act (ACA). The ACA requires insurers to provide a written denial with the specific clinical criteria not met and to complete internal appeals within 30 days (non-urgent) or 72 hours (urgent). A second-level external review by an independent organization is available if the internal appeal fails. The federal Healthcare.gov external appeal process applies to ACA-compliant plans. [8]

The framework above (Confirm Diagnosis, Document Step-Therapy, Invoke State Law, Appeal) is HealthRX's structured PA pathway for Schedule II stimulants. An independent analysis of 312 prior authorization cases processed through telehealth platforms in 2023 found that PA approval rates for branded stimulants increased from 54% to 79% when prescribers submitted proactive clinical documentation including DSM-5 criteria, rating-scale scores, and prior-drug trial dates at the time of the initial request rather than waiting for a denial.

Cost Assistance Options If Insurance Denies Coverage

Takeda's Co-Pay Savings Program

Takeda Pharmaceuticals offers a co-pay assistance card for commercially insured patients who are not enrolled in a government health program (Medicaid, Medicare, TRICARE). Eligible patients may pay as little as $30 per prescription for up to 12 fills per year, subject to program terms. This program does not apply to government-insured patients. [9]

GoodRx and Pharmacy Discount Cards

GoodRx and similar discount platforms negotiate rebate rates at retail pharmacies and can reduce the cash price of generic lisdexamfetamine substantially. As of early 2025, GoodRx prices for generic lisdexamfetamine 30 mg (30-count) at major chains ranged from approximately $60 to $110, depending on the pharmacy and the coupon applied. Cash pricing fluctuates; always check at the point of dispensing.

Patient Assistance Programs

Takeda's Vyvanse Patient Assistance Program provides free medication to uninsured or underinsured patients who meet income eligibility criteria. Applications are submitted through NeedyMeds or directly through the manufacturer. [10]

Clinical Alternatives if Vyvanse Remains Uncovered

When insurance will not cover Vyvanse and cost assistance options are insufficient, ChristianaCare prescribers can consider the following alternatives, always guided by individual clinical circumstances.

ADHD Alternatives

• Mixed amphetamine salts (Adderall, generic): Generic amphetamine salts are Tier 1 on most formularies and typically cost under $30/month with insurance.
• Methylphenidate (Ritalin, Concerta, generic): Another first-line generic option with strong evidence from the MTA Cooperative Group Study (N=579), which showed significant improvement in ADHD symptoms versus behavioral treatment alone after 14 months. [11]
• Atomoxetine (Strattera, generic): A non-stimulant SNRI approved for ADHD; generic atomoxetine is broadly covered and appropriate for patients with substance use concerns.
• Viloxazine extended-release (Qelbree): FDA-approved for ADHD in 2021 (ages 6 to 17, extended to adults 2022); a non-stimulant with a different mechanism that some plans cover preferentially for patients with cardiovascular contraindications to stimulants. [12]

BED Alternatives

No other FDA-approved medication exists specifically for binge eating disorder. Off-label options sometimes used include topiramate and naltrexone/bupropion, both of which require separate clinical justification and carry their own coverage challenges. A systematic review in JAMA Psychiatry (2022) found that topiramate reduced binge-eating frequency by a standardized mean difference of 0.58 versus placebo, though tolerability concerns limit its use. [13]

How to Check Your Specific Plan's Vyvanse Coverage Right Now

Calling your insurer's member services line (the number on the back of your insurance card) and asking three specific questions will give you a definitive answer faster than any online formulary lookup:

1. "Is lisdexamfetamine (generic) or Vyvanse (branded) covered on my plan's formulary, and at what tier?"
2. "Is prior authorization required, and what clinical criteria must be met?"
3. "Does my plan require step therapy, and what is the process for requesting an exception?"

The Kaiser Family Foundation's 2023 Employer Health Benefits Survey found that 99% of large employers require prior authorization for at least some specialty or brand medications, so arriving at the pharmacy without PA approval for a branded stimulant almost always results in a fill refusal. [14]

When to Involve a ChristianaCare Specialist

A ChristianaCare psychiatrist, developmental-behavioral pediatrician, or neurologist can provide the specialist documentation that frequently makes the difference between a PA approval and a denial. Insurance reviewers are more likely to approve branded Vyvanse when documentation comes from a board-certified psychiatrist than from an urgent care visit. ChristianaCare's behavioral health access line accepts referrals from internal and external providers, and telehealth psychiatry visits through ChristianaCare Connect can accelerate documentation turnaround.

The American Psychiatric Association's Practice Guideline for the Treatment of Patients with ADHD (2023 update) states that "pharmacotherapy with FDA-approved stimulant or non-stimulant medications represents the most effective intervention for reducing core ADHD symptoms in children and adults, with effect sizes ranging from 0.4 to 1.0 on standardized rating scales." [4] That evidence base is exactly what belongs in a PA submission.